BACKGROUND: MicroRNAs play important roles in the development and progression of various cancers. Recent studies have shown that miR-638 was downregulated in several tumors; however, its role in gastric cancer (GC) has not been investigated in detail. AIMS: The purpose of this study was to determine the role of miR-638 and to elucidate its regulatory mechanism in GC. METHODS: The expression levels of miR-638 and specificity protein 2 (Sp2) were detected by real-time PCR and Western blotting in GC. After pcDNA6.2-GW/EmGFP-miR-638 vector, miR-638 inhibitor and Sp2-siRNA transfection, the AGS cell proliferation was investigated by MTT assay and cell cycle, and apoptosis was detected using the Annexin V/PI. In addition, the regulation of Sp2 by miR-638 was evaluated by real-time RT-PCR, Western blot and luciferase reporter assays; cyclin D1 expression was measured by Western blotting. RESULTS: The expression of miR-638 is dramatically down-regulated and Sp2 expression is remarkably up-regulated in GC tissues. Luciferase assays revealed that miR-638 inhibited Sp2 expression by targeting the 3'-UTR of Sp2 mRNA. Overexpression of miR-638 and Sp2-siRNA reduced Sp2 expression at both the mRNA and protein levels in vitro, and inhibition of miR-638 increased Sp2 expression. Moreover, we found that miR-638 overexpression and Sp2-siRNA markedly suppressed cell proliferation with decreasing expression of cyclin D1 and inducing G1-phase cell-cycle arrest in vitro; inhibition of miR-638 significantly promoted cell proliferation by increasing expression of cyclin D1 and leading more cells into the S and G2/M phase. CONCLUSIONS: Our results demonstrated that miR-638 suppressed GC cell proliferation by targeting Sp2 with influence on the expression of cyclin D1. We suggest that miR-638 might be a candidate predictor or an anticancer therapeutic target for GC patients.
BACKGROUND: MicroRNAs play important roles in the development and progression of various cancers. Recent studies have shown that miR-638 was downregulated in several tumors; however, its role in gastric cancer (GC) has not been investigated in detail. AIMS: The purpose of this study was to determine the role of miR-638 and to elucidate its regulatory mechanism in GC. METHODS: The expression levels of miR-638 and specificity protein 2 (Sp2) were detected by real-time PCR and Western blotting in GC. After pcDNA6.2-GW/EmGFP-miR-638 vector, miR-638 inhibitor and Sp2-siRNA transfection, the AGS cell proliferation was investigated by MTT assay and cell cycle, and apoptosis was detected using the Annexin V/PI. In addition, the regulation of Sp2 by miR-638 was evaluated by real-time RT-PCR, Western blot and luciferase reporter assays; cyclin D1 expression was measured by Western blotting. RESULTS: The expression of miR-638 is dramatically down-regulated and Sp2 expression is remarkably up-regulated in GC tissues. Luciferase assays revealed that miR-638 inhibited Sp2 expression by targeting the 3'-UTR of Sp2 mRNA. Overexpression of miR-638 and Sp2-siRNA reduced Sp2 expression at both the mRNA and protein levels in vitro, and inhibition of miR-638 increased Sp2 expression. Moreover, we found that miR-638 overexpression and Sp2-siRNA markedly suppressed cell proliferation with decreasing expression of cyclin D1 and inducing G1-phase cell-cycle arrest in vitro; inhibition of miR-638 significantly promoted cell proliferation by increasing expression of cyclin D1 and leading more cells into the S and G2/M phase. CONCLUSIONS: Our results demonstrated that miR-638 suppressed GC cell proliferation by targeting Sp2 with influence on the expression of cyclin D1. We suggest that miR-638 might be a candidate predictor or an anticancer therapeutic target for GC patients.
Authors: Vinod Gopalan; Suja Pillai; Faeza Ebrahimi; Ali Salajegheh; Tommy C Lam; Tran K Le; Nicole Langsford; Yik-Hong Ho; Robert A Smith; Alfred K-Y Lam Journal: Mol Carcinog Date: 2013-09-05 Impact factor: 4.784
Authors: Tae-Hyung Kim; Shannon L Chiera; Keith E Linder; Carol S Trempus; Robert C Smart; Jonathan M Horowitz Journal: Cancer Res Date: 2010-10-19 Impact factor: 12.701
Authors: Katarzyna Kozar; Maria A Ciemerych; Vivienne I Rebel; Hirokazu Shigematsu; Agnieszka Zagozdzon; Ewa Sicinska; Yan Geng; Qunyan Yu; Shoumo Bhattacharya; Roderick T Bronson; Koichi Akashi; Piotr Sicinski Journal: Cell Date: 2004-08-20 Impact factor: 41.582
Authors: Annesa Flentje; Kord M Kober; Adam W Carrico; Torsten B Neilands; Elena Flowers; Nicholas C Heck; Bradley E Aouizerat Journal: Brain Behav Immun Date: 2018-03-13 Impact factor: 7.217